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Background: Obesity plays an important role in the pathogenesis of hypertension. Renal dopamine D1-like
receptor-mediated diuresis and natriuresis are impaired in the obese Zucker rat, an obesity-related hypertensive
rat model. The role of arterial D1 receptors in the hypertension of obese Zucker rats is not clear.
Methods: Plasma glucose and insulin concentrations and blood pressure were measured. The vasodilatory
response of isolated mesenteric arteries was evaluated using a small vessel myograph. The expression and
phosphorylation of D1 receptors were quantified by co-immunoprecipitation and immunoblotting To determine
the effect of hyperinsulinemia and hyperglycemia on the function of the arterial D1 receptor, we studied obese
Zucker rats (six to eight-weeks old) fed (6 weeks) vehicle or rosiglitazone, an insulin sensitizer (10 mg/kg per day)
and lean Zucker rats (eight to ten-weeks old), fed high-fat diet to induce hyperinsulinemia or injected
intraperitoneally with streptomycin (STZ) to induce hyperglycemia.
Results: In obese Zucker rats, the vasorelaxant effect of D1-like receptors was impaired that could be ascribed to
decreased arterial D1 receptor expression and increased D1 receptor phosphorylation. In these obese rats,
rosiglitazone normalized the arterial D1 receptor expression and phosphorylation and improved the D1-like
receptor-mediated vasorelaxation. We also found that D1 receptor-dependent vasorelaxation was decreased in lean
Zucker rats with hyperinsulinemia or hyperglycemia but the D1 receptor dysfunction was greater in the former than
in the latter group. The ability of insulin and glucose to decrease D1 receptor expression and increase its
phosphorylation were confirmed in studies of rat aortic smooth muscle cells.
Conclusions: Both hyperinsulinemia and hyperglycemia caused D1 receptor dysfunction by decreasing arterial D1
receptor expression and increasing D1 receptor phosphorylation. Impaired D1 receptor-mediated vasorelaxation is
involved in the pathogenesis of obesity-related hypertension.
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There is an increasing incidence of metabolic syndrome
(MS) which is characterized by abdominal obesity, hypertri-
glyceridemia, low serum high density lipoprotein choles-
terol, elevated blood pressure, and elevated fasting plasma
glucose [1]. The metabolic syndrome can cause or intensify
cardiovascular, as well as renal disease [1,2]. One of the
possible etiologies of the metabolic syndrome is insulin re-
sistance associated with hyperinsulinemia [1-4]. The stimu-
latory effect of insulin on sympathetic drive [5], vascular
smooth muscle growth [6] and sodium and water retention
[7] and its inhibitory effect on prostacyclin synthesis [8]
have been suggested to be involved in the pathogenesis of
obesity-related hypertension.
Dopamine, a well recognized neurotransmitter in the
central nervous system, is also an important modulator of
renal and adrenal function, sodium balance, and blood
pressure. Dopamine receptors are classified into two sub-
families: the D1-like receptor subfamily includes the D1
and the D5 receptors, while the D2, D3 and D4 receptors
belong to the D2-like receptor subfamily. Dysfunction of
the renal dopaminergic system is implicated in the patho-
genesis and/or maintenance of hypertension [9,10].
The obese Zucker rat is a model of metabolic syndrome
characterized by hyperinsulinemia, hyperglycemia, and
hypertension. Dopamine has been implicated in the devel-
opment of obesity, caused, in part, by increased food intake
due to decreased dopaminergic function, specifically the D2
receptor, in the central nervous system [11,12]. D1 receptor
mediated-natriuresis and diuresis are also impaired in obese
Zucker rats [13,14]. Although the kidney is important in the
long-term regulation of blood pressure [15], hypertension is
also accompanied by increased vascular resistance [16].
Dopamine receptors are expressed in resistance vessels. In
the rat mesenteric artery, D1 and D5 receptors are expressed
in the tunica media while D2-like receptors are expressed
mainly at the adventitia-tunica media transitional zone. The
increase in blood pressure with aging has been related to a
decrease in the expression of arterial D1, D2, and D5 recep-
tor [17]. However, the role of the arterial D1 receptor in the
hypertension of obese Zucker rats is not clear. Our current
study tested the hypothesis that the vasorelaxant effect of
the D1 receptor is impaired in obese Zucker rats.
Methods
Animal experiments
Male obese Zucker rats and age-matched male lean Zucker
rats were housed in plastic cages and fed normal rodent
chow and tap water. Twelve obese Zucker rats (six to eight-
weeks old) were randomly divided into two groups: 1) one
group consisted of obese rats treated (6 weeks) with oral
rosiglitazone maleate (10 mg/kg, suspended in 1% carboxy
methyl cellulose in distilled water); and 2) the other group
consisted of obese control rats treated with the vehicle (1%carboxy methyl cellulose). Eighteen lean Zucker rats (eight
to ten-weeks old) were randomly divided into three groups:
1) control rats fed normal diet and treated with vehicle; 2)
rats fed control diet and treated with STZ (single intraperi-
toneal injection, 65 mg/kg); and 3) rats fed high-fat diet
(with 50% fat-derived calories) for one month.
All experiments were approved by the Daping Hospital
Animal Use and Care Committee and all procedures
were approved by the Experimental Animals Committee
of Daping Hospital.
Blood pressure and plasma glucose and insulin
measurements
After an overnight fast, obese and lean Zucker rats were
anesthetized with pentobarbital (Nembutal) with an initial
dose of 60 mg/kg, followed by constant infusion at 40 mg/
kg/hr [18]. Following a tracheotomy, the left carotid artery
was catheterized with polyethylene-50 tubing for blood
pressure monitoring. Blood pressure and heart rate were
allowed to stabilize for 10 minutes [19] before accepting
the blood pressure and heart rate observed as baseline.
The abdomen was opened to expose the abdominal aorta
and blood samples were collected from the aorta in
EDTA-coated tubes for measurement of plasma glucose
and insulin, and then the rats were sacrificed by an over-
dose of pentobarbital (100 mg/kg body wt). Plasma glu-
cose concentrations were determined by using Accu-Chek
Advantage glucose monitoring system. Plasma insulin
levels were measured by a rat insulin 96-well plate assay
(Millipore Co., St Charles, MO).
Preparation and study of small resistance arteries
Each rat was anesthetized with sodium pentobarbital
(60 mg/kg). The entire mesenteric bed was removed care-
fully and placed in ice-cold physiological salt solution (PSS)
containing (mM):NaCl 119, KCl 4.7, CaCl2·H2O 2.5,
MgSO4·H2O 1.17, NaH2CO3 25, KH2PO4 1.18, EDTA
0.027, and glucose 5.5, adjusted to pH 7.4. The mesenteric
artery was carefully and quickly dissected from the sur-
rounding fat and connective tissues. Third-order branches
of the superior mesenteric artery (resting arterial diameter:
200 ± 20 μm) were cut into rings approximately 2 mm in
length, and mounted on 40 μm stainless-steel wires in an
isometric Mulvany-Halpern small-vessel myograph (model
91 M610, J.P. Trading, Science Park, Aarhus, Denmark)
[20]. One wire was attached to a force transducer and the
other to a micrometer so that wall tension can be measured
at a predetermined internal diameter. The rings were main-
tained in PSS at 37°C and continuously bubbled with oxy-
gen (95%) and carbon dioxide (5%) (Carbogen) [21]. The
dissecting procedures were performed with extreme care to
protect the endothelium from inadvertent damage, proved
by a normal response to acetylcholine (Ach) (10-5 Ach-
induced relaxation >80% of basal values of arteries
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some vessels, the endothelium was removed by pulling a
hair along the inside of the vessel; successful denudation of
the endothelium was confirmed by the absence of relax-
ation with Ach (10-5M) [22]. Following mounting, the
arterial ring was equilibrated in PSS for 1 hr at 37°C at a
wall tension of 0.1 mN/mm. Based on preliminary data
from >100 vessels, we confirmed that a normalized cir-
cumference (L0) = 0.9 L100 resulted in maximal active
force development. The vessels were studied at L0 in all
subsequent protocols. After determining the response to
Ach, as indicated above, the vessels were rinsed three
times with fresh PSS and allowed to recover to baseline
for 15 minutes. In the first set of experiments, the rings
were contracted with phenylephrine HCl (10-5M) and
high-potassium PSS (KPSS, 125 mM) to obtain the max-
imal response. After obtaining the maximal response to
PHE (10-5M), the response curves to fenoldopam, a D1 re-
ceptor agonist [9,10], were measured by a cumulative
concentration-dependent protocol (10-9 to 10-5M). Re-
sponse to every single concentration of fenoldopam was
observed for 2 minutes. To test the vasorelaxant specific
effects of D1 receptors, the arteries were incubated with
the D1-like receptor antagonist SCH23390 (10
-7M) for
30 minutes before fenoldopam treatment. In order to de-
termine specificity of the vasodilatory effect of D1 receptor
stimulation, we studied the vasodilation induced by so-
dium nitroprusside (SNP, 10-10 to 10-4M) in PHE-
preconstricted mesenteric arteries.
Cell and sample preparation
Embryonic thoracic aortic smooth muscle cells from
normotensive Berlin–Druckrey IX rats (A10, ATCC,
Hercules, CA) were cultured at 37°C in 95% air/5% CO2
atmosphere in Dulbecco’s Modified Eagle’s Medium.
A10 cells (80% confluence) and mesenteric arteries from
Zucker rats were flash frozen by liquid nitrogen and ho-
mogenized in ice-cold lysis buffer (5 ml/gm tissue)
(20 mM Tris-HCl, pH 7.4; 2 mM EDTA, pH 8.0; 2 mM
EGTA; 100 mM NaCl; 10 μg/ml leupeptin; 10 μg/ml apro-
tinin; 2 mM phenylmethylsulfonyl fluoride; 1% NP-40),
sonicated, kept on ice for 1 hr, and centrifuged at 16,000 g
for 30 minutes. All samples were stored at -70°C until use.
Immunoblotting
After boiling the homogenates in sample buffer (35 mmol/
L Tris-HCl, pH 6.8, 4% SDS, 9.3% dithiothreitol, 0.01% bro-
mophenol blue, 30% glycerol) at 95°C for 5 min, 100 μg of
protein were separated by SDS-PAGE (10% polyacryl-
amide), and then electroblotted onto nitrocellulose mem-
branes (Bio-Rad). The blots were blocked overnight with
5% nonfat dry milk in phosphate buffered saline with
Tween 20 (PBST) (0.05% Tween 20 in 10 mmol/l phos-
phate buffered (isotonic) saline) at 4°C with constantshaking, then incubated with polyclonal rabbit anti-rat D1
receptor antibodies (1:400 dilution; Millipore) overnight in
the cold-room at 4°C. The membranes were then further
incubated with infrared- labeled secondary antibodies
(donkey anti-rabbit IRDye 800, Li-Cor Biosciences, Lin-
coln, NE) added to bind to the primary antibody at room
temperature for 1 hr. The membranes were washed three
times with PBST. The bound complex was detected using
the Odyssey Infrared Imaging System (Li-Cor Biosci-
ences). The images were analyzed using the Odyssey Ap-
plication Software to obtain the integrated intensities.
Determination of basal D1 receptor phosphorylation by
co-immunoprecipitation
Equal amounts of lysates (1.0 mg protein/ml supernatant
from A10 cells or mesenteric artery) were incubated
with polyclonal antiphosphoserine antibody (HKSP, New
Territories, HK) (2.5 μg/ml) for 1 hr and protein-G agarose
at 4°C for 12 hr. The immunoprecipitates were pelleted and
washed four times with lysis buffer. The pellets were sus-
pended in sample buffer, boiled for 10 min, and subjected to
immunoblotting with polyclonal affinity-purified rabbit anti-
rat D1 receptor antibody. In order to determine the specifi-
city of the bands, normal rabbit IgG (negative control) and
D1 receptor antibody (positive control) were used as the
immunoprecipitants [23]. The bound complexes were de-
tected using the Odyssey Infrared Imaging System (Li-Cor
Biosciences). The images were analyzed using the Odyssey
Application Software to obtain the integrated intensities.
Materials
Fenoldopam, rosiglitazone maleate, STZ, mitogen-activated
protein kinase (MAPK) inhibitor PD98059, Ach, SNP, PHE,
and D1 receptor antagonist SCH23390 were obtained from
Sigma-Aldrich (St. Louis, MO). Rabbit anti-rat D1 receptor
polyclonal antibodies and rat insulin 96 well plate assay kit
were obtained from Millipore Corporation (St Charles,
MO); and anti-phosphoserine antibodies were obtained
from Abcam Ltd (New Territories, Hong Kong, China).Statistical analysis
The data are expressed as mean ± SEM. Comparison within
groups was made by repeated measures ANOVA (or paired
t-test when only 2 groups were compared), and comparison
among groups (or t-test when only 2 groups were com-
pared) was made by factorial ANOVA with Holm-Sidak test.
A value of P< 0.05 was considered significant.
Results
D1 receptor-mediated vasorelaxant effect is impaired in
mesenteric arteries from obese Zucker rats
Consistent with previous reports [24], several variables, in-
cluding body weight, and fasting plasma glucose and insulin
Table 1 General and biochemical parameters of lean and obese Zucker rats (12-14 weeks old)
Lean control Obese control Obese+ROG Lean+HFD Lean+STZ
Body weight (g) 273.83±5.37 439.64±7.34* 425.72±8.26 305.80±3.77* 222.79±3.38*
Plasma glucose (mmol/L) 5.86±0.17 8.88±0.48* 5.94±0.27# 6.22±0.15 >33.00*
Plasma insulin (ng/ml) 0.79±0.02 7.94±1.04* 2.97±0.44# 2.19±0.32* 0.46±0.06*
Mean blood pressure 118.91±1.85 138.26±3.62* 124.85±2.51# 120.59±2.39 129.66±1.51*
Values are means ±SE; n=6. *P < 0.05 vs. lean control rats; #P < 0.05 vs. obese control rats.
Obese rats were treated with rosiglitazone (ROG): 10mg/kg/day for 6 weeks; Lean rats were treated with high fat diet (HFD) and streptozotocin (STZ) for 4 weeks.
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obese than lean Zucker rats (Table 1). Fenoldopam, the
D1 receptor agonist, (10
-7M to 10-5M) induced a
concentration-dependent vasorelaxation in the third-
order mesenteric arteries from lean Zucker ratsFigure 1 Relaxation of phenylephrine (PHE)-preconstricted rat mesen
nitroprusside (SNP). Rat mesenteric arterial rings from obese and lean Zu
preconstricted with PHE (10-5M) and then treated with varying concentratio
(C): D1-like receptor specificity of fenoldopam-induced vasorelaxation in rat
rats were preconstricted with PHE, and then incubated with fenoldopam (F
(D): Rat mesenteric arterial rings from obese and lean Zucker rats with end
with varying concentrations of SNP (10-10-10-4M) (P = NS lean vs obese, n =(Figure 1A). The absence of endothelium did not affect
the fenoldopam-induced vasorelaxation, indicating that
the fenoldopam-induced vasorelaxation was endothelium-
independent (Figure 1B). The vasorelaxant effect of
fenoldopam was via a D1-like receptor because a D1-teric arterial rings in response to fenoldopam and sodium
cker rats with (E+) (A) or without (E-) endothelium (B) were
ns of fenoldopam (Fen, 10-9-10-5M) (*P < 0.01 vs. obese rats, n = 8).
mesenteric arterial rings. Rat mesenteric arterial rings from lean Zucker
en, 10-6M) and/or SCH23390 (SCH, 10-7M) (*P < 0.01 vs. Fen, n = 6).
othelium (E+) were preconstricted with PHE (10-5M) and then treated
5).
Figure 2 D1 receptor expression and phosphorylation in mesenteric arteries from lean and obese Zucker rats. (A): D1 receptor
expression was determined by immunoblotting. (B): Serine-phosphorylated D1 receptor in rat mesenteric arteries was determined by
co-immunoprecipitation and immunoblotting. Normal rabbit IgG (negative control) or D1 receptor antibody (positive control) was used as the
immunoprecipitant. D1 receptor serine phosphorylation was normalized by D1 receptor protein. (*P < 0.05 vs. lean rats, n = 6).
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the fenoldopam-induced vasorelaxation (Figure 1C), al-
though SCH23390, by itself, was without any effect.
The impaired vasorelaxant effect of fenoldopam was
not a generalized phenomenon, because sodium nitro-
prusside (10-10 to 10-4M)-mediated vasodilation was
not impaired in obese Zucker rats, consistent with pre-
vious reports [25,26] (Figure 1D).
To determine whether or not the arterial D1 receptor is
involved in the pathogenesis of obesity-related hyperten-
sion, we studied the D1 receptor function in third-order
mesenteric arteries from obese Zucker rats. We found that
the fenoldopam-induced vasorelaxation was lost in
obese Zucker rats in the presence (Figure 1A) or absence
(Figure 1B) of the endothelium. The dysfunction of renal
D1 receptor in hypertension [27] and obese Zucker rats
[28,29] has been reported to be caused by basal hyperpho-
sphorylation of the renal D1 receptor. To determine
whether or not this phenomenon also exists in third order
mesenteric arteries of obese Zucker rats, D1 receptor ex-
pression and phosphorylation was studied by immuno-
blotting and immunoprecipitation. We found that D1
receptor expression was lower (Figure 2A), while basal D1
receptor phosphorylation (Figure 2B) in third order mes-
enteric arteries was higher in obese than lean Zucker rats.
Roles of hyperinsulinemia and hyperglycemia in the D1
receptor vascular dysfunction in obese Zucker rats
The pathogenesis of obesity is complex. To determine
whether or not high plasma levels of glucose and insulin areinvolved in the obesity-related hypertension, the obese
Zucker rats were treated with the insulin sensitizer [30],
rosiglitazone (10 mg/kg oral, daily). We found that rosiglita-
zone restored the impaired fenoldopam-mediated vasorelax-
ation in obese Zucker rats (Figure 3A), increased the
decreased D1 receptor expression (Figure 3B), and decreased
the increased phosphorylation (Figure 3C) of D1 receptor in
mesenteric arteries from obese Zucker rats consistent with
those reported in the kidney [28].
Consistent with other reports [28,30], our current study
found that rosiglitazone reduced plasma insulin and glucose
levels and blood pressure (Table 1). Therefore, it was diffi-
cult to determine whether hyperinsulinemia, hyperglycemia,
or both led to the dysfunction of the arterial D1 receptor.
To overcome this dilemma, we used the hyperinsulinemic
and hyperglycemic lean Zucker rat models. Lean Zucker
rats fattened by a high-fat diet for one month developed
hyperinsulinemia but had normal blood pressure, similar to
other reports [31,32]. To establish a hyperglycemia model,
lean Zucker rats were intraperitoneally injected with a single
dose of STZ (65 mg/kg) [33]; the STZ-treated lean Zucker
rats would be expected to develop slightly high blood pres-
sure and hyperglycemia but with low plasma insulin levels
(Table 1), as described by others [34]. We found that both
hyperinsulinemic (Figure 4A) and hyperglycemic (Figure 4B)
lean Zucker rats had impaired D1 receptor-mediated vasore-
laxation, accompanied by decreased D1 receptor expression
(Figure 4C) and increased D1 receptor phosphorylation
(Figure 4D), but the dysfunction of the D1 receptor was
greater in the hyperinsulinemia than hyperglycemia
Figure 3 Effect of rosiglitazone on D1 receptor expression and function in mesenteric arteries from obese Zucker rats. The mesenteric
arteries from obese Zucker rats, treated with rosiglitazone (ROG) or vehicle, were incubated with varying concentrations of fenoldopam
(10-9-10-5M). The vasorelaxation with fenoldopam is shown in 3A (*P < 0.05, vs. obese rats, n = 8 repeated measures ANOVA, Holm-Sidak test)
while D1 receptor expression or phosphorylation in mesenteric arteries, determined by immunoblotting or co-immunoprecipitation, is shown in
3B and 3C, respectively. D1 receptor serine phosphorylation was normalized by D1 receptor protein. (*P < 0.05, vs. obese rats, n = 6),
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role than hyperglycemia in the impairment of arterial
D1 receptor-mediated relaxation (Figures 4A-D).
Effect of insulin and glucose on D1 receptor expression
and phosphorylation in A10 cells
To further confirm the in vivo results, the effects of high in-
sulin and high glucose concentrations on D1 receptor expres-
sion and phosphorylation were studied in A10 cells, a rat
thoracic aorta-derived smooth muscle cell line. Treatment
with insulin (Figures 5A and 5B) or high glucose (Figures 5C
and 5D) decreased D1 receptor expression and increased D1
receptor phosphorylation. In the presence of a MAP kinaseinhibitor, PD98059 (10-6 M), the effects of insulin on D1 re-
ceptor expression and phosphorylation were blocked, indicat-
ing that MAP kinase is involved in the signaling pathway
(Figures 6A and 6B).
Discussion
Role of hyperinsulinemia in obesity-related hypertension
Obesity is a well-known risk factor for hypertension
[15,35]. Indeed, risk estimates according to the Framing-
ham study show that roughly 80% of essential hyperten-
sion in men and 65% in women can be directly
attributed to obesity [36]. It is accepted that insulin re-
sistance is epidemiologically linked with hypertension
Figure 4 D1 receptor expression and function in lean Zucker rats with hyperinsulinemia or hyperglycemia. Lean Zucker rats were fed high-fat diet
(HFD) to induce hyperinsulinemia or intraperitoneally injected with streptomycin (STZ) to induce hyperglycemia. The mesenteric arteries preconstricted with
PHE from those rats were treated with varying concentrations of fenoldopam (Fen, 10-9-10-5M) (A and B) (*P < 0.05, vs. lean Zucker rats, n = 8). D1 receptor
expression was determined by immunoblotting (C) and D1 receptor phosphorylation (D) was determined by co-immunoprecipitation and immunobloting.
D1 receptor serine phosphorylation was normalized by D1 receptor protein (*P < 0.05, vs. obese rats, n = 6).
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with insulin resistance increases renal sodium reabsorption
and sympathetic activity and leads to elevated arterial pres-
sure [39]. Insulin resistance and compensatory hyperinsuli-
nemia impair the production of nitric oxide and favor the
production of vasoconstrictors [40-42]. Our current study
found hyperinsulinemia, hyperglycemia, and elevated blood
pressure in obese Zucker rats that were reduced by rosiglita-
zone treatment similar to previous reports [43,44]. We also
found that lean Zucker rats fed a high fat diet had hyperin-
sulinemia and STZ-treated lean Zucker rats were hypergly-
cemic and hypoinsulinemic, similar to other reports [31,45].
Impairment of D1 receptor-mediated vasodilation
is involved in obesity-related hypertension
Dopamine has been reported as an important modulator
of sodium balance, renal and adrenal function, and bloodpressure and is relevant to the pathogenesis and/or
maintenance of hypertension. In humans with essential
hypertension and rodents with genetic hypertension
(SHRs and Dahl salt-sensitive rats), D1-like receptor
agonist-mediated natriuretic and diuretic responses are
impaired [46,47]. The ability of D1-like receptors to
stimulate adenylyl cyclase activity in renal arteries is also
impaired in SHRs [48] and we have also reported an im-
paired ability of D1 receptors to dilate the mesenteric
arteries of SHRs [49]. Other studies have shown that
the D1 receptor is hyperphosphorylated and uncoupled
from G protein subunits, leading to the D1 receptor dys-
function in SHRs, which precedes the onset of hyperten-
sion and co-segregates with the hypertensive phenotype
[10,50]. Thus, D1 receptor dysfunction is a primary de-
fect in the hypertension of SHRs. Lokhandwala et al
have found that obese Zucker rats have defective renal
Figure 5 Effect of insulin and glucose on D1 receptor expression and phosphorylation in A10 cells. A10 cells were treated with varying
concentrations of insulin (A and B) or glucose (C and D) for 24 hrs. D1 receptor expression was determined by immunoblotting. A10 cells were
treated with insulin (10-7M) and glucose (35 mM) for 24 hrs. D1 receptor expression and phosphorylation were determined by co-immunoprecipitation
or immunoblotting. D1 receptor serine phosphorylation was normalized by D1 receptor protein (*P < 0.05, vs. control, n = 5).
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ceptor expression and ability to inhibit Na, K-ATPase
and Na,H-exchanger activities in renal proximal tubules
[13,28,30]. These authors suggested that the renal dopa-
minergic dysfunction in obese Zucker rats is acquired
and not inherited [14] and could be ameliorated by
inhibition of reactive oxygen species production by tem-
pol and insulin sensitization by rosiglitazone [28,29].
Because increased peripheral vascular resistance and al-
tered vascular reactivity are distinctive features of es-
sential hypertension [16], we tested the hypothesis that
the hypertension of obese Zucker rats may be caused
by an impairment of D1 receptor-mediated vasodilation.
This was indeed the case as the D1 receptor-mediatedvasorelaxation was impaired in obese Zucker rats. This dys-
function of the D1 receptor could be ascribed to the de-
creased D1 receptor expression and increased D1 receptor
phosphorylation because the rosiglitazone-mediated ameli-
oration of the impaired D1 receptor relaxant effect was asso-
ciated with an increase in D1 receptor expression and a
decrease in D1 receptor phosphorylation. Rosiglitazone, a
PPARγ agonist, has many effects on the cardiovascular sys-
tem independent of its insulin sensitizing effects, including
anti-inflammation and direct stimulation of NO production
[51]. Whether or not such mechanisms were involved in the
rosiglitazone-mediated improvement of the vasodilatory ef-
fect of the D1 receptor in the current report needs to be de-
termined in a future study.
Figure 6 Role of MAP kinase in the regulation by insulin of D1 receptor expression and phosphorylation in A10 cells. A10 cells were
treated with insulin (10-7M) in the presence or absence of the MAP kinase inhibitor PD98059 (10-6M) for 24 hrs. D1 receptor expression (A) or
phosphorylation (B) was determined by immunoblotting or co-immunoprecipitation. D1 receptor serine phosphorylation was normalized by D1
receptor protein. (*P < 0.01, vs. control; #P < 0.05, vs. insulin, n = 5).
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dysfunction of arterial D1 receptor in obese Zucker rats
Obese Zucker rats have increased plasma insulin and fasting
glucose levels [24,52,53]. As stated above, treatment of obese
Zucker rats with rosiglitazone reduced plasma insulin and
glucose levels and improved the vasorelaxant effect of
fenoldopam that was associated with an increase in the
vascular expression of D1 receptor and a decrease in
vascular serine-phosphorylated D1 receptor. Thus,
hyperinsulinemia and hyperglycemia may be involved
in the defective fenoldopam-mediated relaxation in
small mesenteric arteries isolated from obese Zucker
rats. In order to identify the mechanisms that caused
the impaired D1 receptor vasodilatory function in obese
Zucker rats, we used two rat models: high fat diet-
induced hyperinsulinemia and STZ-induced type 1
diabetes in lean Zucker rats. The former rat model is
characterized by insulin resistance and hyperinsuline-
mia [31,32] while the latter rat model is character-
ized by hyperglycemia and low plasma insulin levels
[33,34]. After the establishment of hyperinsulinemia or
hyperglycemia, mesenteric arteries had an impaired
fenoldopam-mediated vasorelaxation that was more
evident in the high fat diet-fed hyperinsulinemic rats
than STZ-induced type I diabetic rats. Therefore, both
hyperinsulinemia and hyperglycemia are involved in the
dysfunction of the arterial D1 receptor, but hyperinsuli-
nemia plays a more important role than hyperglycemia
in this phenomenon.
The ability of increased insulin and glucose concentra-
tions to decrease D1 receptor expression and increaseD1 receptor phosphorylation in vivo was confirmed
in vitro in A10 cells. Treatment of A10 cells with insu-
lin decreased D1 receptor expression and increased
D1 receptor phosphorylation, consistent with the findings
in renal proximal tubule cells [54,55]. Mitogen-activated
protein kinase (MAPK) is activated in cardiovascular
diseases such as diabetes and hypertension [56,57]. The
up-regulation of MAPK reduces renal D1 receptor affinity
and G-protein coupling in obese rats [58]. The current
studies also showed that blockade of MAPK reversed
both the decreased D1 receptor expression and increased
D1 receptor phosphorylation caused by high insulin in
A10 cells.Limitations
Besides of the role of hyperinsulinemia and hypergly-
cemia in the D1-receptor mediated arterial dysfunction,
adiponectin, as an important adipose tissue-derived
factor, might have some effect on dopamine function.
For example, monosodium glutamate induces obesity
in rodents markedly decreases adiponectin levels [59]
and compromises dopaminergic systems [60]. More-
over, dopamine stimulates adiponectin release [61],
and antidiabetic treatment in Zucker diabetic fatty
rats inhibits the development of hypo-adiponectinemia
in mesenteric resistance arteries, but is not able to im-
prove adiponectin induced vasodilation [62]. Whether
or not the plasma adiponectin would affect arterial
dopamine receptor function needs to be determined in
the future study.
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In summary, this study shows that both hyperinsulinemia
and hyperglycemia impair vascular D1 receptor function
that is associated with decreased D1 receptor expression
and increased D1 receptor phosphorylation. Besides, hyper-
insulinemia plays a more important role than hypergly-
cemia in the dysfunction of the arterial D1 receptor in
obese Zucker rats. Impaired D1 receptor-mediated vasore-
laxation is involved in the pathogenesis of obesity-related
hypertension.
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